BD Veritor™ Plus System | Home

There's a life behind every test

A family sightseeing while traveling
Clock icon

Fast, Reliable Results

BD Veritor Plus Analyzer icon

Convenient Portability

Nasal sample icon

Simple Sample Collection

Computer screen icon

Easy Reporting Options

The BD Veritor™ Plus System offers convenient point-of-care testing for SARS-CoV-2*, Influenza A+B, Group A Streptococcus, and respiratory syncytial virus and combines rapid, reliable results with ease of implementation and simple workflow options.

Possibility in Action

Rapid antigen testing to fit your needs

The BD Veritor™ Plus System is engineered to make rapid antigen testing simple and reliable. Our portable, convenient Analyzer is easy-to-operate, and delivers timely results at the point of care.

The Value of Diagnostic Testing

Point-of-care rapid antigen testing

When a respiratory infection hits, results cannot be delayed. Rapid diagnostic testing plays a key role in informing healthcare professionals to make quick care decisions.

One system, multiple possibilities

The faster you know which infection is present, the faster you can respond.

The BD Veritor™ Plus System fits seamlessly into your workflow. The reliable, convenient system allows you to easily provide testing where and when it is needed, delivering rapid, informative results you can trust.

Articles and studies in multiple peer-reviewed publications including the New England Journal of Medicine1 and the British Medical Journal2 have touted the benefits of serial, rapid antigen testing. In addition, a recent landmark RADx-funded study demonstrated that the serial use of diagnostic tests (at least twice per week), including rapid antigen tests, increased the ability to detect infection3.  The BD Veritor™ System for the Rapid Detection of SARS-CoV-2* supports this approach in everyday locations such as schools and businesses, along with serial testing in other situations, such as athletes and teams to ensure safe games and competitions.


  1. New England Journal of Medicine, November 26, 2020; 383:e120, DOI: 10.1056/NEJMp2025631
  2. BMJ 2021;372:n208

** In patient care settings meeting Provincial guidelines and requirements for point-of-care testing